DE60325725D1 - Monoklonaler antikörper gegen aurora-a, seine herstellungsverfahren und seine verwendung zur diagnose und zur behandlung von krebs - Google Patents

Monoklonaler antikörper gegen aurora-a, seine herstellungsverfahren und seine verwendung zur diagnose und zur behandlung von krebs

Info

Publication number
DE60325725D1
DE60325725D1 DE60325725T DE60325725T DE60325725D1 DE 60325725 D1 DE60325725 D1 DE 60325725D1 DE 60325725 T DE60325725 T DE 60325725T DE 60325725 T DE60325725 T DE 60325725T DE 60325725 D1 DE60325725 D1 DE 60325725D1
Authority
DE
Germany
Prior art keywords
mab
monoclonal antibody
diagnosis
optionally
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60325725T
Other languages
German (de)
English (en)
Inventor
Claude Prigent
Anne Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SANG BRETAGNE ETS FRANC
Centre National de la Recherche Scientifique CNRS
Etablissement Francais du Sang
Original Assignee
SANG BRETAGNE ETS FRANC
Centre National de la Recherche Scientifique CNRS
Etablissement Francais du Sang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SANG BRETAGNE ETS FRANC, Centre National de la Recherche Scientifique CNRS, Etablissement Francais du Sang filed Critical SANG BRETAGNE ETS FRANC
Application granted granted Critical
Publication of DE60325725D1 publication Critical patent/DE60325725D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE60325725T 2002-06-12 2003-06-12 Monoklonaler antikörper gegen aurora-a, seine herstellungsverfahren und seine verwendung zur diagnose und zur behandlung von krebs Expired - Lifetime DE60325725D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0207212A FR2840905B1 (fr) 2002-06-12 2002-06-12 Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers
PCT/FR2003/001772 WO2003106500A1 (fr) 2002-06-12 2003-06-12 Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers

Publications (1)

Publication Number Publication Date
DE60325725D1 true DE60325725D1 (de) 2009-02-26

Family

ID=29595167

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60325725T Expired - Lifetime DE60325725D1 (de) 2002-06-12 2003-06-12 Monoklonaler antikörper gegen aurora-a, seine herstellungsverfahren und seine verwendung zur diagnose und zur behandlung von krebs

Country Status (9)

Country Link
US (1) US7514231B2 (https=)
EP (1) EP1511771B1 (https=)
JP (1) JP4555681B2 (https=)
AT (1) ATE420115T1 (https=)
AU (1) AU2003255671A1 (https=)
CA (1) CA2489214C (https=)
DE (1) DE60325725D1 (https=)
FR (1) FR2840905B1 (https=)
WO (1) WO2003106500A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005061519A1 (en) 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
EP1778669A2 (en) 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase inhibitors
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1655369A1 (en) * 1995-12-18 2006-05-10 Sugen, Inc. Diagnosis and treatment of AUR-1 and/or AUR-2 related disorders

Also Published As

Publication number Publication date
FR2840905B1 (fr) 2006-07-07
US20070117163A1 (en) 2007-05-24
ATE420115T1 (de) 2009-01-15
AU2003255671A8 (en) 2003-12-31
FR2840905A1 (fr) 2003-12-19
WO2003106500A1 (fr) 2003-12-24
CA2489214A1 (fr) 2003-12-24
AU2003255671A1 (en) 2003-12-31
JP2006513135A (ja) 2006-04-20
EP1511771A1 (fr) 2005-03-09
JP4555681B2 (ja) 2010-10-06
CA2489214C (fr) 2013-08-06
US7514231B2 (en) 2009-04-07
EP1511771B1 (fr) 2009-01-07

Similar Documents

Publication Publication Date Title
ATE538809T1 (de) Verfahren zur auswahl von geeigneten patienten für den wt1-impfstoff
WO2005084109A3 (en) Cancer specific gene mh15
DE60239059D1 (de) Verfahren und zusammensetzungen zur hemmung, prävention oder verringerung des tumorzellwachstums beingen einer antiöstrogen-therapie resistent sind
DE69717664D1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
Ratkaj et al. Microarray analysis of Dupuytren’s disease cells: the profibrogenic role of the TGF-β inducible p38 MAPK pathway
WO2014197937A1 (en) Methods for detecting prostate cancer
Mak et al. Parathyroid hormone-related protein (PTHrP) modulates adhesion, migration and invasion in bone tumor cells
ATE447715T1 (de) Automatische glykofingerabdruck-strategie
RU2013113314A (ru) Способы выявления антител против не4 и способы диагностики и/или прогнозирования состояний, ассоциированных с экспрессирующими не4 клетками
WO2016203053A3 (en) Methods of characterising cancer
CN1928563A (zh) 乳腺癌的免疫组化诊断试剂盒和测试片
DE60325725D1 (de) Monoklonaler antikörper gegen aurora-a, seine herstellungsverfahren und seine verwendung zur diagnose und zur behandlung von krebs
WO2024252184A3 (en) Anti-cldn18_2 antibody and an in vitro diagnostic kit
RU2013104137A (ru) Изоформы bard1 при раке легкого и колоректальном раке и их применение
RU2007141930A (ru) Способ in vitro идентификации соединений для лечения рака
IL190401A0 (en) Antibodies against april as biomarkers for early prognosis of lymphoma patients
FR2919061B1 (fr) Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal.
WO2004040312A3 (fr) Proceded de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
WO2003068268A3 (en) Treatment, diagnosis and imaging of disease
DE60221115D1 (de) Zusammensetzungen und verfahren zur verwendung von fibronektin-fragmenten bei krebsdiagnose
DE50313393D1 (de) Verfahren zur diagnose von entzündungserkrankungen und infektionen mittels bestimmung von lasp-1/ lap-1
ATE406579T1 (de) Verfahren zur diagnose von tumoren
EA200802356A1 (ru) Способ выявления и диагностики злокачественного новообразования, включающий праймеры и зонды для специфичного выявления маркера mage-a3
EA200600012A1 (ru) Полиморфизм человеческого гена nbs1, полезный для диагностики наследственной предрасположенности к раку
JP2013039111A (ja) スプライシングバリアント

Legal Events

Date Code Title Description
8364 No opposition during term of opposition